Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
出版社: Elsevier BV
作者: Xiaohua Wu; Yang Sun; Hongying Yang; Jing Wang; Hanmei Lou; Dan Li; Ke Wang; Hui Zhang; Tao Wu; Yuzhi Li; Chunyan Wang; Guiling Li; Yifeng Wang; Dapeng Li; Ying Tang; Mei Pan; Hongyi Cai; Weihu Wang; Bing Yang; Hua Qian; Qiuhong Tian; Desheng Yao; Ying Cheng; Bing Wei; Xiumin Li; Tao Wang; Min Hao; Xiaohong Wang; Tiejun Wang; Juntao Ran; Hong Zhu; Lijing Zhu; Xianling Liu; Yunxia Li; Lihong Chen; Qingshan Li; Xiaojian Yan; Fei Wang; Hongbing Cai; Yunyan Zhang; Zhiqing Liang; Funan Liu; Yi Huang; Bairong Xia; Pengpeng Qu; Genhai Zhu; Youguo Chen; Kun Song; Meili Sun; Zhengzheng Chen; Qiang Zhou; Lina Hu; Guzhalinuer Abulizi; Hongyan Guo; Sihai Liao; Yijing Ye; Ping Yan; Qiu Tang; Guoping Sun; Ting Liu; Dongmei Lu; Mingxiu Hu; Zhongmin M Wang; Baiyong Li; Michelle Xia
